Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions (NEVO RES-I)
A Randomized, Multi-Center, Single-Blind Comparison of the Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution Versus the TAXUS Liberte Paclitaxel-eluting Coronary Stent System in De Novo Native Coronary Artery Lesions
Sponsor: Conor Medsystems
Terminated
The NEVO™ stent will not be commercialized. Cordis have decided to close the study after 3 years. This decision took the absence of safety signals into account.
This NA trial investigates Coronary Atherosclerosis and is currently terminated or withdrawn. Conor Medsystems leads this study, which shows 11 recorded versions since 2008 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Terminated NA
-
Sep 2025 — Dec 2025 [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Dec 2021 — Jul 2024 [monthly]
Terminated NA
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Nov 2020 — Jan 2021 [monthly]
Terminated NA
-
Jun 2018 — Nov 2020 [monthly]
Terminated NA
-
May 2018 — Jun 2018 [monthly]
Terminated NA
-
Aug 2017 — May 2018 [monthly]
Terminated NA
-
Jan 2017 — Aug 2017 [monthly]
Terminated NA
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Conor Medsystems
- Cordis US Corp.
For direct contact, visit the study record on ClinicalTrials.gov .